Loading organizations...
Founded in 2015 by Doctor Shlomit Yehudai-Reshef and Professor Roni Michaely, Gina Life develops an artificial intelligence diagnostic platform for the early detection of ovarian cancer and endometriosis through vaginal secretion analysis. The primary commercial product is an at-home test kit designed to provide accessible screening for high-risk individuals and the general population. To validate this proprietary machine learning technology, the enterprise conducted clinical trials involving over 1,000 participants to establish a proof of concept. Led by Chief Executive Officer Inbal Zafir-Lavie, the firm secured backing from the MindUP incubator in 2020 and won the MassChallenge accelerator against 400 contestants while completing the Mayo Clinic program. Approaching its Series A funding round, the company planned a United States clinical trial initiation for the second quarter of 2023 to prepare for a product launch.
Gina Life has raised $3.0M across 1 funding round.
Gina Life has raised $3.0M in total across 1 funding round.
Gina Life has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2023 | $3M Seed | — | Pitango Venture Capital, Alive Israel Healthtech Fund, MindUP Digital Health Incubator, Technion | Announced |
Gina Life has raised $3.0M in total across 1 funding round.
Gina Life's investors include Pitango Venture Capital, ALIVE Israel HealthTech Fund, MindUP Digital Health Incubator, Technion.
Gina Life is an Israel-based femtech startup founded in 2015, developing an AI-powered platform for early detection of women's health diseases, primarily ovarian cancer, through analysis of vaginal discharge biomarkers.[1][2][3] The company creates a simple test pad or home-testing kit that captures secretions, uses machine learning to identify key proteins, and generates personalized results via a mobile app, targeting at-risk women, those with ovarian pathologies, and the general population to address late diagnosis issues.[1][2][4] It serves women globally, solving the problem of undetected diseases like ovarian cancer, endometrial cancer, and endometriosis by enabling affordable, non-invasive screening that reduces male bias in diagnostics and hospital burdens.[2][3][5] As of 2023, Gina Life (now Nevia Bio) completed a $3.1M seed round, conducted trials with over 1,000 participants, and initiated US proof-of-concept studies, earning awards like Frost & Sullivan's 2022 Israeli Technology Innovation Leadership.[2][4][8]
Gina Life emerged from personal tragedy and scientific curiosity. Dr. Inbal Zafir-Lavie, CEO with a PhD in Immunology from the Technion, lost her sister to late-diagnosed ovarian cancer, inspiring her to co-found the company in 2015 with Dr. Shlomit Yehudai-Reshef, a molecular biologist and CSO who directs Rambam Health Care Campus's Clinical Research Institute.[2][3][5] Yehudai-Reshef's 2006 research explored vaginal discharge as an untapped biomarker source for diseases like ovarian cancer and endometriosis, overcoming initial skepticism to identify 32 promising proteins, narrowed to 3-5 via AI.[3] Early milestones include Rambam MedTech support, winning MassChallenge Boston in an unspecified year, joining MindUP incubator in 2020, and Mayo Clinic accelerator participation.[3][4] By 2022-2023, it advanced to US trials at sites like Mayo Clinic and rebranded to Nevia Bio after seed funding.[4][8]
Gina Life rides the femtech boom, a growing market projected at billions per indication, fueled by AI/ML in diagnostics, post-pandemic at-home testing acceptance, and demands to close gender gaps in healthcare where ovarian cancer's late detection causes high mortality.[2][4][5] Timing aligns with women's health investments rising globally, democratizing access in developed and developing nations via non-invasive tech that eases hospital loads.[2][5] It influences the ecosystem by pioneering vaginal secretion analysis, inspiring fluid-based biomarker research, and partnering with institutions like Mayo Clinic and Technion, accelerating FDA/CMS paths and data collection for broader AI health tools.[3][4][8]
Gina Life (Nevia Bio) is poised for clinic-launched ovarian cancer tests by late 2023, followed by home-use versions, US commercialization post-trials, and pipeline expansions amid femtech growth.[4][5][8] Trends like AI diagnostics, self-testing normalization, and seed funding momentum will propel it, potentially capturing massive markets while evolving influence through global partnerships and revenue from data-driven tools. This positions it to save lives as envisioned—simply and early—transforming women's health from reactive to proactive.
